000140025 001__ 140025
000140025 005__ 20210129212741.0
000140025 0247_ $$2doi$$a10.1093/hmg/dds426
000140025 0247_ $$2ISSN$$a1460-2083
000140025 0247_ $$2ISSN$$a0964-6906
000140025 0247_ $$2WOS$$aWOS:000312651800006
000140025 0247_ $$2altmetric$$aaltmetric:1138364
000140025 0247_ $$2pmid$$apmid:23059812
000140025 037__ $$aFZJ-2013-05988
000140025 041__ $$aEnglish
000140025 082__ $$a570
000140025 1001_ $$0P:(DE-HGF)0$$aCirstea, I. C.$$b0
000140025 245__ $$aDiverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes
000140025 260__ $$aOxford$$bOxford Univ. Press$$c2013
000140025 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1385717068_9544
000140025 3367_ $$2DataCite$$aOutput Types/Journal article
000140025 3367_ $$00$$2EndNote$$aJournal Article
000140025 3367_ $$2BibTeX$$aARTICLE
000140025 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140025 3367_ $$2DRIVER$$aarticle
000140025 500__ $$3POF3_Assignment on 2016-02-29
000140025 520__ $$aActivating somatic and germline mutations of closely related RAS genes (H, K, N) have been found in various types of cancer and in patients with developmental disorders, respectively. The involvement of the RAS signalling pathways in developmental disorders has recently emerged as one of the most important drivers in RAS research. In the present study, we investigated the biochemical and cell biological properties of two novel missense KRAS mutations (Y71H and K147E). Both mutations affect residues that are highly conserved within the RAS family. KRASY71H showed no clear differences to KRASwt, except for an increased binding affinity for its major effector, the RAF1 kinase. Consistent with this finding, even though we detected similar levels of active KRASY71H when compared with wild-type protein, we observed an increased activation of MEK1/2, irrespective of the stimulation conditions. In contrast, KRASK147E exhibited a tremendous increase in nucleotide dissociation generating a self-activating RAS protein that can act independently of upstream signals. As a consequence, levels of active KRASK147E were strongly increased regardless of serum stimulation and similar to the oncogenic KRASG12V. In spite of this, KRASK147E downstream signalling did not reach the level triggered by oncogenic KRASG12V, especially because KRASK147E was downregulated by RASGAP and moreover exhibited a 2-fold lower affinity for RAF kinase. Here, our findings clearly emphasize that individual RAS mutations, despite being associated with comparable phenotypes of developmental disorders in patients, can cause remarkably diverse biochemical effects with a common outcome, namely a rather moderate gain-of-function.
000140025 536__ $$0G:(DE-HGF)POF2-452$$a452 - Structural Biology (POF2-452)$$cPOF2-452$$fPOF II$$x0
000140025 588__ $$aDataset connected to CrossRef, juser.fz-juelich.de
000140025 7001_ $$0P:(DE-Juel1)145165$$aGremer, L.$$b1$$ufzj
000140025 7001_ $$0P:(DE-HGF)0$$aDvorsky, R.$$b2
000140025 7001_ $$0P:(DE-HGF)0$$aZhang, S. -C.$$b3
000140025 7001_ $$0P:(DE-HGF)0$$aPiekorz, R. P.$$b4
000140025 7001_ $$0P:(DE-HGF)0$$aZenker, M.$$b5
000140025 7001_ $$0P:(DE-HGF)0$$aAhmadian, M. R.$$b6$$eCorresponding author
000140025 773__ $$0PERI:(DE-600)1474816-2$$a10.1093/hmg/dds426$$gVol. 22, no. 2, p. 262 - 270$$n2$$p262 - 270$$tHuman molecular genetics$$v22$$x1460-2083$$y2013
000140025 8564_ $$uhttp://hmg.oxfordjournals.org/content/22/2/262
000140025 8564_ $$uhttps://juser.fz-juelich.de/record/140025/files/FZJ-2013-05988.pdf$$yRestricted
000140025 909CO $$ooai:juser.fz-juelich.de:140025$$pVDB
000140025 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145165$$aForschungszentrum Jülich GmbH$$b1$$kFZJ
000140025 9132_ $$0G:(DE-HGF)POF3-559H$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vAddenda$$x0
000140025 9131_ $$0G:(DE-HGF)POF2-452$$1G:(DE-HGF)POF2-450$$2G:(DE-HGF)POF2-400$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bSchlüsseltechnologien$$lBioSoft$$vStructural Biology$$x0
000140025 9141_ $$y2013
000140025 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000140025 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000140025 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000140025 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000140025 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000140025 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000140025 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000140025 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000140025 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000140025 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000140025 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000140025 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000140025 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000140025 920__ $$lyes
000140025 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x0
000140025 980__ $$ajournal
000140025 980__ $$aVDB
000140025 980__ $$aUNRESTRICTED
000140025 980__ $$aI:(DE-Juel1)ICS-6-20110106
000140025 981__ $$aI:(DE-Juel1)IBI-7-20200312